Pulse Biosciences enters the final week of September with a wave of fresh analyst coverage colliding against a stock that has pulled back 4.5% on the week and carries a meaningful short position — yet the lending market is quietly loosening.
The analyst angle is the week's standout development. BTIG initiated coverage just this morning with a Buy rating and a $70 price target — the highest on the Street. That follows Freedom Capital Markets kicking off at Buy with a $73 target earlier this month, and Needham initiating at Buy with a $58 target in August. All five analysts covering PLSE carry Buy ratings. The consensus target of $54 sits only marginally above the current $52.69 close, which understates the individual bull cases — targets range from $58 to $73, suggesting the average is dragged down by Canaccord's $43 (raised from $32 after the August earnings print). The rapid accumulation of fresh coverage is notable for a small-cap medical device name: four initiations in roughly four months signals that the buy-side is actively building positions and demanding research.
The bull case centres on PLSE's proprietary NPS (Nano-Pulse Stimulation) technology for atrial fibrillation ablation and the prospect of partnerships with major device players. Bears point to an intensely competitive market, deep negative earnings (the P/E and EV/EBITDA multiples are both deeply negative, reflecting a pre-profitability company), and the execution risk around commercialization and regulatory approval. The ORTEX analyst recommendation divergence factor scores in the 95th percentile — the Street is unusually aligned to the bullish side relative to history. EPS surprise ranks in the 79th percentile, consistent with a company that has been beating its own low bar.
The lending market tells a story of easing pressure after a period of tightness. Availability has recovered to roughly 47% — about one share available for every two borrowed — after dropping as low as 5% in mid-August and spending much of late August and early September below 25%. That was a meaningfully constrained borrow environment; the relief since September 9 is significant. Short interest itself is modest, running at about 4.6% of free float (just over 3.1 million shares), up roughly 1.7% on the week and 3.8% over the past month, but far from squeeze territory. Cost to borrow has eased considerably from levels above 2.6% in mid-August, now running near 1.2% — cheap enough that maintaining a short position carries little carry cost. Options positioning is mildly bullish: the put/call ratio of 0.26 is slightly below its 20-day average and running near the lower half of its 52-week range, reflecting call-heavy positioning rather than defensive hedging.
The ownership picture is dominated by one name. Robert Duggan holds approximately 71.9% of shares outstanding, as last disclosed in a Schedule 13D/A filed in May 2026 — a position he has been actively building, having acquired roughly 660,000 additional shares at $19.69 in May. Duggan's concentrated activist stake means the free float is limited, which partly explains why even modest short interest creates relatively elevated SI-as-percentage-of-float readings. On the insider side, Chief Operating Officer Liane Teplitsky made a series of open-market purchases of approximately $50,000 each on August 26, 28, and 31 and September 1 — steady, unplanned accumulation at prices between $48 and $50, below the current level. The 90-day net insider flow is positive at roughly $200,000 in value. Duggan's 13D status is worth flagging: Schedule 13D/G disclosures are event-driven around the 5% threshold, and his stake is "as last disclosed."
Earnings are next scheduled for November 6. The two most recent prints both drove strong positive reactions — the August result produced an 11.9% one-day move and an 18.5% five-day follow-through, while the prior print moved 4.7% on the day and 10.3% over five sessions. Both instances delivered gains, not losses, which helps explain why options positioning is skewed toward calls rather than protection. The short score has been running in a tight band between 74.6 and 75.6 all month, suggesting no dramatic change in the composite short-side pressure signal.
What to watch: whether the flood of fresh analyst initiations translates into price target upgrades as the commercialization story develops, and whether borrow availability — now recovering from August's squeeze lows — continues to loosen ahead of the November earnings event.
See the live data behind this article on ORTEX.
Open PLSE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
